Core Viewpoint - Y-mAbs Therapeutics, Inc. is set to hold a virtual Radiopharmaceutical R&D update on May 28, 2025, focusing on its ongoing clinical trials and pipeline strategy for cancer treatment [1][2]. Group 1: Upcoming Event Details - The virtual update will cover Part A clinical data from the ongoing Phase 1 GD2-SADA clinical trial, including pharmacokinetic and dosimetry data [2]. - The update will also include information on nonclinical optimization studies for the GD2-SADA asset and plans for clinical implementation [2]. - The duration of the update is expected to be 90 minutes, with a live audio webcast available on the company's Investor Relations website [3]. Group 2: Company Overview - Y-mAbs is a commercial-stage biopharmaceutical company focused on developing novel radioimmunotherapy and antibody-based therapeutic products for cancer treatment [4]. - The company utilizes technologies such as the Self-Assembly DisAssembly (SADA) Pretargeted Radioimmunotherapy Platform (PRIT) and bispecific antibodies generated using the Y-BiClone platform [4]. - The product pipeline includes DANYELZA® (naxitamab-gqgk), the first FDA-approved treatment for relapsed or refractory high-risk neuroblastoma in specific patient populations [4].

Core Viewpoint - Y-mAbs Therapeutics reported solid financial results for Q1 2025, highlighting growth in DANYELZA net product revenue and advancements in its SADA PRIT platform, while also managing operational costs prudently [2][4][20]. Financial Results - Total net product revenues for Q1 2025 were $20.9 million, an 8% increase from $19.4 million in Q1 2024 [4][7]. - U.S. DANYELZA net product revenues decreased by 28% to $13.4 million, while Ex-U.S. revenues increased by $6.7 million to $7.5 million [8][9]. - Gross profit remained stable at $17.9 million, with gross margins of 86% in Q1 2025 compared to 89% in Q1 2024 [14]. - Operating costs included $11.4 million in R&D expenses, down from $13.3 million in the previous year, and $13.1 million in SG&A expenses, up from $11.4 million [15][16]. - The net loss for Q1 2025 was $5.2 million, or ($0.12) per share, an improvement from a net loss of $6.6 million, or ($0.15) per share, in Q1 2024 [18]. Corporate Developments - The National Comprehensive Cancer Network updated its guidelines to include DANYELZA as a Category 2A treatment option for high-risk neuroblastoma [5]. - The first patient was dosed in the Phase 1 clinical trial (Trial 1201) for CD38-SADA pretargeted radioimmunotherapy in relapsed/refractory non-Hodgkin Lymphoma [5][6]. - The company plans to host a virtual R&D update on May 28, 2025, to discuss clinical data and future strategies [4][12]. Cash Position and Guidance - As of March 31, 2025, Y-mAbs had cash and cash equivalents of $60.3 million, expected to support operations into 2027 [19][25]. - The company reiterated its full-year 2025 revenue guidance of $75 million to $90 million and projected Q2 2025 revenues between $17 million and $19 million [20][21].

Summary of Bolt Biotherapeutics Conference Call Company Overview - **Company**: Bolt Biotherapeutics (BOLT) - **Focus**: Development of immuno-oncology therapeutics, specifically targeting cancer through innovative antibody platforms Key Points Discussed Financial Overview - As of March 31, cash, cash equivalents, and marketable securities totaled **$58 million** [4] - Funding expected to support key milestones, including the Phase 1 trial for BDC3042 through mid-2026 [4] Clinical Programs - **BDC3042**: A first-in-class dectin-2 agonist antibody aimed at treating cancer - Phase 1 trial results presented at the American Association for Cancer Research (AACR) Annual Meeting [4][25] - **Enrollment**: 17 patients, including those with non-small cell lung cancer (NSCLC) [26] - **Safety Profile**: Well tolerated with no grade 4 or 5 adverse events reported [28] - **Efficacy**: Evidence of tumor size reduction in patients with prior treatments, particularly in NSCLC [31][37] - **BDC4182**: A next-generation immune-stimulating antibody conjugate (ISAC) targeting claudin 18.2 - Enrollment for the first-in-human Phase 1 study has opened in Australia [42] - Targeting advanced gastric and gastroesophageal cancers [50] Mechanism of Action - **BDC3042**: Engages and activates dectin-2 on tumor-associated macrophages (TAMs), converting them into tumor-destructive cells [11][12] - **Clinical Observations**: Enhanced immune response noted, particularly in patients previously treated with checkpoint inhibitors [12][60] Preclinical Data - BDC3042 shows promising preclinical results, indicating potential for broad applicability across various cancer types [15][18] - Evidence of tumor regression in preclinical models, supporting the mechanism of action [19][20] Market Potential - BDC4182 aims to capture a broader market by targeting not only high expressers of claudin 18.2 but also moderate and low expressers [44][81] - The approved drug for claudin 18.2 currently addresses about **38%** of the gastric cancer market [81] Collaboration and Partnerships - Ongoing discussions for partnerships to accelerate the development of BDC3042, with a goal to secure a non-binding term sheet by June 6 [39] - Collaboration with Genmab and Toray to advance multiple development programs [52][53] Future Outlook - Anticipated updates on patient recruitment for BDC4182 and partner selection for BDC3042 by fall [54] - Emphasis on efficiency in the current biotech financing environment to develop product candidates that could improve patient outcomes [54] Additional Insights - The conference highlighted the importance of safety and tolerability in early-phase trials, especially for heavily pretreated patients [28][37] - The potential for BDC3042 to be effective in combination with other therapies, particularly in immunogenic tumors like NSCLC [60][61] - The company is focused on differentiating its ISAC platform from competitors by improving linker payloads and reducing immunogenicity [95][96] This summary encapsulates the critical aspects of the conference call, providing insights into Bolt Biotherapeutics' current status, clinical programs, and future directions in the oncology space.

Core Insights - Bolt Biotherapeutics reported financial results for Q1 2025, highlighting advancements in their immunotherapy pipeline and a cash balance of $58 million to fund operations through mid-2026 [1][4][10]. Business Update - The company is advancing its pipeline of novel immunotherapies, with promising early clinical data for BDC-3042 presented at AACR 2025 and the opening of enrollment for BDC-4182 [2][4]. - BDC-3042, a proprietary agonist antibody targeting dectin-2, showed a favorable safety profile and anti-tumor activity in a Phase 1 study for patients with metastatic solid tumors [5]. - BDC-4182, targeting claudin 18.2, has opened for enrollment and demonstrated complete regressions in preclinical models [5]. Financial Performance - Collaboration revenue decreased to $1.2 million in Q1 2025 from $5.3 million in Q1 2024, primarily due to the completion of performance obligations under a previous agreement [10]. - Research and Development (R&D) expenses were $9.5 million in Q1 2025, down from $16.5 million in Q1 2024, attributed to reduced clinical expenses and restructuring [10]. - General and Administrative (G&A) expenses also decreased to $3.8 million from $5.8 million year-over-year [10]. - The net loss for Q1 2025 was $11.0 million, compared to a net loss of $10.8 million in Q1 2024 [12]. Cash Position - As of March 31, 2025, the company had cash, cash equivalents, and marketable securities totaling $58 million, expected to support operations through mid-2026 [4][10].

Agenus (AGEN) Q1 2025 Earnings Call May 12, 2025 08:30 AM ET Company Participants Zack Armen - Head of IR & Corporate DevelopmentDr. Garo Armen - Chairman & CEORichard Goldberg - Chief Development OfficerChristine Klaskin - Vice President of Finance, Principal Financial Officer & Principal Accounting OfficerSteven O’Day - Chief Medical OfficerJennifer Buell - Chairman & Executive CouncilMayank Mamtani - Senior Managing Director & Group Head of HealthcareMatt Phipps - Group Head - Biotechnology Conference Ca ...

First site initiated for Phase 3 OVATION 3 study of IMNN-001 in treatment of newly diagnosed advanced ovarian cancer New data from Phase 2 OVATION 2 study of IMNN-001 accepted for oral presentation at 2025 ASCO Annual Meeting Company to hold conference call today at 11:00 a.m. ET LAWRENCEVILLE, N.J., May 12, 2025 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage company in Phase 3 development with its DNA-mediated immunotherapy, today reported financial results for the three months ended Mar ...

PRINCETON, N.J., May 09, 2025 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers, today announced that on May 5, 2025, PDS Biotech granted a nonstatutory stock option to purchase 5,000 shares of common stock to an employee in its clinical department as a material inducement to such employee’s employment and in accordance with Nasdaq Listing Rule 5635(c)(4 ...

MIAMI, May 09, 2025 (GLOBE NEWSWIRE) -- SAB BIO (Nasdaq: SABS), (“SAB BIO” or the “Company”), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that is developing human anti-thymocyte immunoglobulin (hIgG) for delaying the onset or progression of type 1 diabetes (T1D), today announced financial results for the quarter ending March 31, 2025, and reported on recent developments. Samuel J. Reich, Chairman and CEO of SAB BIO, stated, “We have made strong progress this quarter on our ...

Werewolf Therapeutics (HOWL) 2025 Conference May 08, 2025 10:00 AM ET Speaker0 Alright. We're gonna go ahead and get started. Welcome and good morning everyone to the second day of the Citizens Life Sciences Conference. It's my pleasure to introduce the next presenting company, Werewolf Therapeutics. Presenting for the company is Randy Isaacs, the Chief Medical Officer. Welcome Randy, thanks for joining us. Speaker1 Oh, Ren, thank you so much for having us. Speaker0 So I never know exactly who's in the audi ...

ALK (ALKB:DC / OMX: ALK B) today announced that Health Canada has approved ALK’s regulatory filing for ITULATEK® (tree pollen sublingual allergy immunotherapy tablet) for treatment of children and adolescents aged five to 17. Accordingly, the tree pollen tablet is now indicated for treatment of moderate to severe seasonal allergic rhinitis, with or without conjunctivitis, induced by pollen from birch, alder, hazel, and/or oak, in children, adolescents, and adults five to 65 years of age in Canada. Outside ...